Joseph Saluri Net Worth

Joseph Saluri biography

Joseph B. Saluri J.D. serves as Independent Director of the Company. Since August 2018, Mr. Saluri has served as chairman of the board and chief executive officer of BlueAllele, LLC, a start-up biotechnology company. Mr. Saluri previously served as executive vice president and general counsel for, Calyxt, Inc. from June 2017 to March 2018. Prior to his employment with Calyxt, Inc., Mr. Saluri served as vice president and general counsel for Stine Seed Company and its affiliates from July 1999 to March 2017. Prior to his employment with Stine, Mr. Saluri practiced as an attorney and solicitor at law with Nicholas Critelli Associates, PC, in Des Moines, Iowa and London, England from June 1993 to June 1999. Mr. Saluri served as a director of Newlink Genetics Corporation, a public biopharmaceutical company from May 2010 to July 2017. Mr. Saluri received his J.D. degree from Drake University Law School and his B.S.B.A. degree from Drake University. Our Board believes that Mr. Saluri’s extensive legal background and experience in corporate management, finance and investor relations provides him with the qualifications and skills to serve as a director of our company.

How old is Joseph Saluri?

Joseph Saluri is 53, he's been the Independent Director of Zevra Therapeutics Inc since 2014. There are 3 older and 11 younger executives at Zevra Therapeutics Inc. The oldest executive at Zevra Therapeutics Inc is Richard W. Pascoe, 57, who is the Exec. Chairman.

What's Joseph Saluri's mailing address?

Joseph's mailing address filed with the SEC is C/O KEMPHARM, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, FL, 34747.

Insiders trading at Zevra Therapeutics Inc

Over the last 10 years, insiders at Zevra Therapeutics Inc have traded over $0 worth of Zevra Therapeutics Inc stock and bought 3,083,371 units worth $9,282,809 . The most active insiders traders include Street Capital Master Fund,..., David S Tierney és Travis C Mickle. On average, Zevra Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $246,727. The most recent stock trade was executed by R. La Duane Clifton on 13 January 2023, trading 635 units of KMPH stock currently worth $3,689.

What does Zevra Therapeutics Inc do?

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

Zevra Therapeutics Inc executives and stock owners

Zevra Therapeutics Inc executives and other stock owners filed with the SEC include:

• Travis Mickle,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Travis C. Mickle Ph.D.,
  Co-Founder, Pres, CEO & Director
• Sven Guenther,
  Executive Vice President - Research and Development
• R. LaDuane Clifton,
  Chief Financial Officer, Treasurer, Secretary
• Dr. Travis C. Mickle,
  Co-Founder, Chairman, Pres & CEO
• Dr. Sven Guenther,
  Exec. VP of R&D
• R. LaDuane Clifton CPA,
  CFO, Sec. & Treasurer
• Richard W. Pascoe,
  Exec. Chairman
• Jason Rando,
  IR Contact Officer
• David Tierney,
  Independent Director
• Joseph Saluri,
  Independent Director
• Matthew Plooster,
  Independent Director
• Richard Pascoe,
  Lead Independent Director
• Timothy Sangiovanni,
  Vice President, Corporate Controller
• Timothy J. Sangiovanni CPA,
  VP & Corp. Controller
• Dr. Andrew Barrett,
  VP of Scientific Affairs
• Christal M. M. Mickle,
  Co-Founder and VP of Operations & Product Devel.
• Tracy M Woody,
  Chief Commercial Officer
• Danny L Thompson,
  Director
• Gordon K Johnson,
  Chief Business Officer
• Daniel L Cohen,
  EVP, Govt. & Public Relations
• Christal M M Mickle,
  Chief Product Dev. Officer
• Joshua Schafer,
  CCO & EVP, Bus. Development
• Samuel J Braun,
  10% owner
• Tamara A Favorito,
  Director